The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - MedAssessment
Leadership - MedAssessment
Stock and Other Ownership Interests - MedAssessment
Consulting or Advisory Role - Multiple clients of MedAssessment on safety/pharmacovigilance in therapeutic areas including oncology, diabetes, urology, dermatology, pain, renal and auto-immune disorders
Expert Testimony - cannot disclose; gastro-intestinal disorders therapeutic area
Travel, Accommodations, Expenses - cannot disclose; urology and auto-immune disorders therapeutic areas
First-time in-human study of VMD-928, an allosteric and irreversible TrkA selective inhibitor, in patients with solid tumors or lymphoma.
 
Vincent Chung
Consulting or Advisory Role - Celgene; Five Prime Therapeutics; Ipsen; Perthera
Speakers' Bureau - AstraZeneca; Celgene; Ipsen
 
Ling Wang
Employment - VM Pharma
Leadership - VM Pharma; VM Pharma; VM Pharma; VM Pharma
Stock and Other Ownership Interests - VM Pharma; VM Pharma; VM Pharma; VM Pharma
Patents, Royalties, Other Intellectual Property - VM Pharma; VM Pharma; VM Pharma; VM Pharma
 
Margaret S. Fletcher
No Relationships to Disclose
 
Erminia Massarelli
Consulting or Advisory Role - Genentech/Roche
Speakers' Bureau - AstraZeneca; Merck
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Merck (Inst); Pfizer (Inst); Tessa Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; Pfizer
 
Karen L. Reckamp
Consulting or Advisory Role - Amgen; ARIAD; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Euclises; Exelixis; Guardant Health; Loxo; Precision Health Economics; Seagen; Takeda; Tesaro
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); ARIAD (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Janssen Oncology (Inst); Loxo (Inst); Molecular Partners (Inst); Pfizer (Inst); Seagen (Inst); Xcovery (Inst); Zeno Pharmaceuticals (Inst)
 
Mihaela C. Cristea
Honoraria - AstraZeneca; Boehringer Ingelheim
Consulting or Advisory Role - Boehringer Ingelheim
Speakers' Bureau - AstraZeneca
Research Funding - Trovagene
 
Nikeeta Prajapati
No Relationships to Disclose
 
Aruna Parikh
No Relationships to Disclose
 
Roger Lewis Whiting
Employment - VM Pharma
Leadership - VM Pharma
Stock and Other Ownership Interests - VM Pharma
 
Maggie Wang
Employment - VM Pharma
Stock and Other Ownership Interests - VM Pharma; VM Pharma
 
Jay Wu
Employment - VM Pharma
Leadership - VM Pharma; VM Pharma; VM Pharma; VM Pharma
Stock and Other Ownership Interests - VM Pharma; VM Pharma; VM Pharma; VM Pharma
Patents, Royalties, Other Intellectual Property - VM Pharma; VM Pharma; VM Pharma; VM Pharma